Ebola vaccine in a nasal spray? early trial halted
NCT ID NCT03462004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a nasal spray vaccine against Ebola in 15 healthy adults. The vaccine uses a weakened common cold virus to deliver a piece of the Ebola virus. The study aimed to check safety and immune response, but it was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPIV3/ΔHNF/EbovZ GP vaccine (nasal spray)
What this could lead to
If successful, this could lead to a needle-free Ebola vaccine that is easier to administer in outbreaks.
What could go wrong
This was a very early (phase 1) trial with only 15 participants, and it was terminated early, so we don't have full safety or effectiveness data. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIR Inpatient Unit, Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 21205, United States